For the Inventor, By the Inventor

Enter assignee name

Mountain View, CA, United States of America

Edison Pharmaceuticals, Inc.

USPTO Granted Patents = 28

% Expired Patents = 50.0

EPO Patents = 6

Forward Citations = 637

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Kieron E Wesson (13 out of 26 patents)

Orion D Jankowski (11 out of 20 patents)

Andrew W Hinman (9 out of 22 patents)

4. Paul Mollard (9 out of 26 patents)

5. Guy M Miller (9 out of 22 patents)

6. William Dvorak Shrader (7 out of 22 patents)

7. Bing Wang (3 out of 64 patents)

8. Viktoria Kheifets (3 out of 15 patents)

9. Sidney M Hecht (3 out of 57 patents)

10. Gail Walkinshaw (3 out of 7 patents)

11. Jiangao Song (2 out of 24 patents)

12. Donald R James (2 out of 20 patents)

13. Xianming Jin (2 out of 2 patents)

14. Wei Zhang (2 out of 217 patents)

15. Jian Chen (2 out of 65 patents)

28 patents: Sort by Forward Citations

1. 9567279 - Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols (2017-02-14),

2. 9546132 - 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases (2017-01-17),

3. 9486435 - (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases (2016-11-08),

4. 9464016 - Catechol derivatives for treatment of oxidative stress diseases (2016-10-11),

5. 9447006 - Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers (2016-09-20),

6. 9399612 - Treatment of pervasive developmental disorders with redox-active therapeutics (2016-07-26),

7. 9370496 - Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones (2016-06-21),

8. 9296712 - Resorufin derivatives for treatment of oxidative stress disorders (2016-03-29),

9. 9278085 - Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers (2016-03-08),

10. 9169196 - 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases (2015-10-27),

11. 9162957 - Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols (2015-10-20),

12. 9090576 - [object Object] (2015-07-28),

13. 9073873 - 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases (2015-07-07),

14. 8969420 - Treatment of pervasive developmental disorders with redox-active therapeutics (2015-03-03),

15. 8952071 - (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases (2015-02-10),

Edison Pharmaceuticals, Inc. is a biotechnology company dedicated to developing treatments for rare and inherited mitochondrial diseases. With a focus on patients with orphan diseases that have limited or no available treatments, Edison Pharmaceuticals utilizes its proprietary redox modulation platform to discover and develop novel therapies. Through deep scientific expertise and advanced technology, the company strives to improve the lives of patients and address unmet medical needs in the field of mitochondrial medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

28 Patents

#109 in Mountain View, CA

#2,839 in California

#11,985 in US

#23,212 in the World

Mountain View, CA, United States of America

Edison Pharmaceuticals, Inc.

Forward Citations = 637

24 inventors:

Kieron E Wesson (13 out of 26 patents)

Orion D Jankowski (11 out of 20 patents)

Andrew W Hinman (9 out of 22 patents)

4. Paul Mollard (9 out of 26 patents)

5. Guy M Miller (9 out of 22 patents)

Please report any incorrect information to [email protected]

Loading…